A clinical trial designed specifically for patients with Alport syndrome
CARDINAL is a Phase 2/3 clinical study
evaluating the safety and effectiveness of bardoxolone methyl
(an oral investigational drug) for the treatment of Alport syndrome.
Up to 210 participants will be enrolled in CARDINAL at approximately
60 research centers around the world.
You may be eligible for this study if you:
Are 12 to 60 years of age
Have been genetically diagnosed with Alport syndrome
(if genetic testing is needed, the cost is covered by Reata)
Other eligibility criteria will apply.
To see if you pre-qualify for CARDINAL